gwpharm.com Report : Visit Site

Technical data of the gwpharm.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host gwpharm.com. Currently, hosted in United States and its service provider is Amazon Technologies Inc. .

the related websites

gwpharm.co.uk bloomberg.com medicines.org.uk bbc.com telegraph.co.uk nhs.uk warwickshire.gov.uk netdoctor.co.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

") skip to main content home cookie notification we use cookies to collect information about how our website is used and to improve the visitor experience. you can change your browser's cookie settings at any time. please review our privacy policy for more information. ok search form search search epilepsy patients & caregivers clinicians & researchers investors & media gw’s vision is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs. justin gover chief executive officer recent news jun 06, 2018 gw pharmaceuticals to present at the goldman sachs 39th annual global healthcare conference london, uk, carlsbad, ca, 6 june, 2018: gw pharmaceuticals plc (nasdaq: gwph, gw, the company or the group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that gw management will present at the goldman sachs 39th annual global healthcare conference on wednesday, read more... may 16, 2018 gw pharmaceuticals and u.s. subsidiary greenwich biosciences announce publication in the new england journal of medicine of a phase 3 study of epidiolex® (cannabidiol oral solution) in lennox-gastaut syndrome – first dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in lennox-gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset epilepsy – read more... may 08, 2018 gw pharmaceuticals plc reports fiscal second quarter 2018 financial results and operational progress - positive unanimous vote at epidiolex® (cannabidiol) fda advisory committee meeting – - nda pdufa goal date scheduled for june 27, 2018 - - conference call today at 4:30 p.m. est - read more... view more pharmaceutical development pipeline pharmaceutical development pipeline unpartnered partnered pre-clinic phase 1 phase 2 phase 3 submit approved epidiolex epidiolex dravet syndrome submit epidiolex lennox-gastaut syndrome submit epidiolex tuberous sclerosis phase 3 sativex (u.s.) sativex ms spasticity phase 3 cbdv (gwp42006) gwp42006 (cbdv) epilepsy phase 2 gwp42006 (cbdv) autism spectrum disorders completed phase 1 other gwp42003 (iv) neonatal hypoxic-ischemic encephalopathy phase 1 gwp42002 / gwp42003 glioblastoma completed phase 2 gwp42003 schizophrenia completed phase 2 learn more ╳ search about us history & approach board of directors executive leadership news media faqs image library media contacts 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 contact us company values & code of conduct products & pipeline research & trials therapeutic areas cannabinoid compounds mechanism of action r&d collaborations research papers pipeline epidiolex sativex patient information summary of product characteristics prescriber information epilepsy patients & caregivers for patients for clinicians & researchers research heroes of epilepsy chase's story investors careers uk careers us careers home news contact us legal ©2016 gw pharmaceuticals, plc. all rights reserved

URL analysis for gwpharm.com

http://www.gwpharm.com///about-us/news/media/media-contacts
http://www.gwpharm.com///products-pipeline/research-trials/mechanism-action
http://www.gwpharm.com///investors
http://www.gwpharm.com/products-pipeline/pipeline
http://www.gwpharm.com///patients-caregivers/heroes-epilepsy/chases-story
http://www.gwpharm.com//#main-content
http://www.gwpharm.com///epilepsy-patients-caregivers
http://www.gwpharm.com///about-us/news?year=2012
http://www.gwpharm.com///about-us/news?year=2011
http://www.gwpharm.com///about-us/news?year=2010
http://www.gwpharm.com///about-us/news/media/image-library
http://www.gwpharm.com///about-us/news?year=2016
http://www.gwpharm.com///about-us/news?year=2015
http://www.gwpharm.com///about-us/news?year=2014
http://www.gwpharm.com///products-pipeline/sativex/patient-information

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: GWPHARM.COM
Registry Domain ID: 27875646_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.ascio.com
Registrar URL: http://www.ascio.com
Updated Date: 2017-08-01T18:57:24Z
Creation Date: 2000-05-26T14:20:11Z
Registry Expiry Date: 2018-05-26T14:20:11Z
Registrar: Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA
Registrar IANA ID: 106
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +442070159370
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Domain Status: serverDeleteProhibited https://icann.org/epp#serverDeleteProhibited
Domain Status: serverTransferProhibited https://icann.org/epp#serverTransferProhibited
Domain Status: serverUpdateProhibited https://icann.org/epp#serverUpdateProhibited
Name Server: NS1.NETNAMES.NET
Name Server: NS2.NETNAMES.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-13T01:12:57Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =gwpharm.com

  PORT 43

  TYPE domain

DOMAIN

  NAME gwpharm.com

  CHANGED 2017-08-01

  CREATED 2000-05-26

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
serverDeleteProhibited https://icann.org/epp#serverDeleteProhibited
serverTransferProhibited https://icann.org/epp#serverTransferProhibited
serverUpdateProhibited https://icann.org/epp#serverUpdateProhibited

NSERVER

  NS1.NETNAMES.NET 204.74.108.253

  NS2.NETNAMES.NET 185.83.102.12

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .